You are viewing: North America Leukapheresis Market analysis
Part of: Leukapheresis Market (Global)

The North America Leukapheresis Market was valued at $35.63 Million in 2026 and projected to reach to $55.55 Million by 2031, representing a compound annual growth rate of 9.3%. North America is positioned as a leading market for leukapheresis technologies, driven by high healthcare spending, advanced clinical infrastructure, and strong adoption of cell and gene therapy innovations.

North America Leukapheresis Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

North America Leukapheresis Market Trends and Insights

  • North America's advanced healthcare infrastructure, high adoption of cell therapy technologies, and strong regulatory support are driving market expansion.
  • In North America, increasing prevalence of hematologic malignancies and growing investment in CAR-T cell therapies are accelerating demand for leukapheresis procedures. North America's market growth is underpinned by robust reimbursement frameworks and the presence of leading medical device manufacturers.
  • Throughout the forecast period from 2026 to 2031, North America is expected to maintain its position as a key market due to rising patient awareness and clinical trial activity.
  • North America's healthcare spending and commitment to innovative cancer treatments position the region for sustained market development..

Key Market Statistics

  • CAGR (2026-2031) 9.3% CAGR
  • Market Size, 2026 ~USD 35.63 Million
  • Forecast, 2031 ~USD 55.55 Million
  • Geography North America

North America Leukapheresis Market Overview

Market Valuation & Growth :

North America's leukapheresis market is valued at $35.63 million in 2026 and is projected to reach $55.55 million by 2031, demonstrating a robust CAGR of 9.3%, outpacing the global average of 8.9%.

Advanced Healthcare Infrastructure :

North America benefits from state-of-the-art medical facilities, cutting-edge leukapheresis equipment, and established clinical protocols that support widespread adoption and standardization of cell therapy procedures.

Rising Hematologic Malignancy Prevalence :

Increasing incidence of blood cancers and hematologic disorders across the US and Canada is driving demand for leukapheresis procedures as a critical component of CAR-T cell therapy and other advanced treatment modalities.

Strong Regulatory Support & Reimbursement :

FDA approval pathways, favorable reimbursement policies, and robust healthcare coverage in North America accelerate market expansion and enable broader patient access to leukapheresis-dependent therapies.

North America Leukapheresis Market Dynamics

  • The region's mature regulatory environment and established reimbursement frameworks create favorable conditions for market players.
  • Increasing prevalence of hematologic malignancies, coupled with growing patient awareness and physician adoption of CAR-T and other cellular therapies, will sustain market momentum through 2031. The US dominates the North American market, accounting for the majority of revenue, while Canada represents a secondary but growing opportunity.
  • Continued investment in research and development, expansion of treatment centers, and introduction of next-generation leukapheresis systems will further accelerate growth.
  • Strategic partnerships between medical device manufacturers and healthcare providers will enhance market penetration and drive the projected 9.3% CAGR..

Related Ecosystem

Key Takeaways

  • North America leukapheresis market valued at $35.63M in 2026, forecast to reach $55.55M by 2031 at 9.3% CAGR
  • North America's advanced healthcare infrastructure and strong regulatory environment support rapid market adoption
  • Rising CAR-T cell therapy demand and hematologic malignancy prevalence drive North America market growth
  • North America's robust reimbursement policies and leading device manufacturers sustain competitive advantage through 2031

Leukapheresis Market Report Scope

Report Metric Details
Base Year 2026
Fastest Growing Segment MULTIPLE MYELOMA (Indication)
Forecast Period 2026–2031
Growth Rate CAGR of 8.9% from 2026 to 2031
Largest Segment ACUTE LYMPHOCYTIC LEUKEMIA (Indication)
Market Size Base Year (Billions) ~USD 0.09 (2026)
Revenue Forecast (Billions) ~USD 0.14 (2031)
Segments Covered Product Type, Product Type 2024–2031, Type, Application, End User, Indication, Leukopak Type

North America Leukapheresis Market Report Segmentation

7 segment dimensions are covered across the global market.

By Product Type

  • Devices
  • Disposables
  • Leukapheresis Devices
  • Leukapheresis Disposables

By Product Type 2024–2031

  • Collection Kits & Accessories
  • Filters & Membrane Consumables
  • Tubing Sets & Collection Bag

By Type

  • Australia
  • Belgium
  • Brazil
  • Canada
  • Centrifugal Devices
  • China
  • Diseased Leukopaks
  • France
  • Germany
  • India
  • Isolated Pbmcs
  • Italy
  • Japan
  • Kingdom Of Saudi Arabia (Ksa)
  • Membrane Separators
  • Mexico
  • Mobilized Leukopaks
  • Netherlands
  • New Zealand
  • Non-Mobilized Leukopaks
  • Poland
  • Rest Of Asia Pacific
  • Rest Of Europe
  • Rest Of GCC Countries
  • Rest Of Latin America
  • Rest Of Middle East & Africa
  • South Korea
  • Spain
  • Switzerland
  • Thailand
  • UK
  • United Arab Emirates (UAE)
  • US

By Application

  • Research Applications
  • Therapeutic Applications

By End User

  • Academic & Research Institutes
  • Blood Component Providers & Blood Centers
  • Contract Research Organizations
  • Hospitals & Transfusion Centers
  • Pharmaceutical & Biotechnology Companies

By Indication

  • Acute Lymphocytic Leukemia
  • Chronic Lymphocytic Leukemia
  • Hepatocellular Carcinoma
  • Multiple Myeloma
  • Non-Hodgkin’S Lymphoma
  • Other Indications
  • Pancreatic Cancer

By Leukopak Type

  • Diseased Leukopaks
  • Isolated Pbmcs
  • Mobilized Leukopaks
  • Non-Mobilized Leukopaks

Target Audience

  • Medical Device Manufacturers : Manufacturers of leukapheresis systems and consumables need North America market data to assess market opportunity, competitive positioning, and develop region-specific product strategies for the high-value US and Canadian markets.
  • Pharmaceutical & Biotech Companies : Cell therapy and gene therapy developers require market intelligence on leukapheresis adoption rates and clinical demand to support CAR-T and other cellular therapy commercialization in North America.
  • Healthcare Providers & Hospital Networks : Hospital systems and cancer treatment centers need market insights to justify leukapheresis infrastructure investments, benchmark adoption rates, and plan capacity expansion across North America.
  • Investment & Private Equity Firms : Investors evaluating opportunities in healthcare technology and cell therapy require detailed North America market data to assess growth potential, competitive dynamics, and investment returns in the leukapheresis sector.
  • Healthcare Consultants & Analysts : Consulting firms and research analysts need comprehensive North America market data to support client advisory services, competitive analysis, and strategic planning in the cell therapy and oncology treatment space.

Key Companies in the North America Leukapheresis Market

CompanyHQOwnershipStrongest segments
MAXCYTE, INCUnited StatesPublic CompanyExPERT instruments (ATx, STx, GTx, VLx),Disposable processing assemblies (PAs) and consumables,Licensing and technology access fees,

MAXCYTE, INC

MaxCyte, Inc. is a United States-based biotechnology company founded in 1998 that specializes in cell engineering technologies. As a publicly traded company, MaxCyte operates with 91 employees and develops innovative solutions for cell-based therapies and research applications.

North America vs. other regions

HowNorth America compares to the other 3 regional blocs covered in this market.

Europe
~USD 38.06 Million · 8% wtd CAGR ·
Asia Pacific
~USD 38.39 Million · 9.8% wtd CAGR ·
Latin America
~USD 4.75 Million · 6.6% wtd CAGR ·

Countries within North America - compare and drill down

Country2025 size (native)
USUSD 39.05 Million
CanadaUSD 3.39 Million

Country market size visualization

US
USD 39.05 Million
Canada
USD 3.39 Million

Reasons to Buy this Report

  • Market Size & Growth Trajectory : Access precise valuation data showing North America's leukapheresis market at $35.63M (2026) expanding to $55.55M (2031), enabling accurate revenue forecasting and investment planning for the region.
  • Competitive Landscape Intelligence : Understand market dynamics specific to North America, including key players, market share distribution, and competitive positioning to inform strategic business decisions and market entry strategies.
  • Country-Level Breakdown : Detailed market segmentation for US ($39.05M) and Canada ($3.39M) provides granular insights for targeted market expansion, regional partnerships, and localized go-to-market strategies.
  • Regulatory & Reimbursement Insights : Comprehensive analysis of North American regulatory frameworks, FDA approval pathways, and insurance reimbursement policies to navigate market entry and optimize commercialization strategies.
  • Clinical Adoption & End-User Trends : Data-driven insights into hospital adoption rates, physician preferences, and patient demand patterns across North America to identify growth opportunities and optimize product positioning.

Frequently asked questions

What is the current size of the North America leukapheresis market?

The North America leukapheresis market is estimated at $35.63 million in 2026 and is expected to grow to $55.55 million by 2031.

What is the projected growth rate for North America leukapheresis market?

North America leukapheresis market is projected to grow at a compound annual growth rate (CAGR) of 9.3% from 2026 to 2031.

What factors are driving growth in the North America leukapheresis market?

Key drivers in North America include increasing CAR-T cell therapy adoption, rising hematologic malignancy prevalence, robust reimbursement frameworks, and advanced healthcare infrastructure.

Which segments dominate the North America leukapheresis market?

North America's market is primarily driven by cell therapy applications, particularly CAR-T cell manufacturing and immunotherapy procedures in leading medical centers.

How does North America compare to other regions in leukapheresis adoption?

North America maintains a leading position globally due to its advanced healthcare systems, strong regulatory support, high treatment costs coverage, and concentration of specialized cancer centers.

RESEARCH METHODOLOGY

This study extensively used both primary and secondary sources. The research involved studying various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

This research study involved the usage of comprehensive secondary sources, directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the leukapheresis market. It was also used to identify key players in the market and classify and segment the industry based on trends to the most detailed level. Additionally, significant developments related to market and technology perspectives were noted. A database of the primary industry leaders was also created using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the leukapheresis market. Primary sources from the demand side include healthcare professionals from blood component providers & blood centers, academic & research institutes, pharmaceutical & biotechnology companies, and hospitals & transfusion centers.

A breakdown of the primary respondents is provided below:

BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE PARTICIPANTS, BY COMPANY TYPE, DESIGNATION, AND REGION

Leukapheresis Market
Size, and Share

Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 2: Other designations include sales, marketing, and product managers.

Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the leukapheresis market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.

Leukapheresis Market Top Down and Bottom Up Approach

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Market Definition

Leukapheresis is the process of separating white blood cells from the whole blood. Therapeutic leukapheresis procedures are used to treat hyperleukocytic leukemia, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin’s lymphoma.

Leukopaks are enriched leukapheresis products that contain mononuclear leukocytes (lymphocytes and monocytes) and are used to develop cell-based therapeutics

Key Stakeholders

  • Apheresis device manufacturers and distributors
  • Leukapheresis product manufacturers and distributors
  • Leukopak manufacturers and distributors
  • Pharmaceutical and biotechnology companies
  • Healthcare service providers (including hospitals and transfusion centers)
  • Cancer treatment centers
  • Blood component providers & blood centers
  • Contract research organizations (CROS)
  • Academic and research institutes
  • Government associations
  • Market research and consulting firms
  • Venture capitalists and investors

Report Objectives

  • To define, describe, segment, and forecast the leukapheresis market by type, application, end user, and region, and the leukopaks market, by type, indication, end user, and region
  • To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall leukapheresis market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the leukapheresis market in five main regions (along with their respective key countries), namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players in the leukapheresis market and comprehensively analyze their core competencies and market share
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships

Available customizations:

With the given market data, MarketsandMarkets offers customizations to meet your company’s specific needs. The following customization options are available for the report:
  • Company Information

Detailed analysis and profiling of additional market players (up to 5)

  • Geographic Analysis

Further breakdown of the Rest of Europe leukapheresis market into Austria, Finland, and other countries

Further breakdown of the Rest of Latin America leukapheresis market into Colombia, Chile, and other countries

  • Competitive Landscape Assessment

Market share analysis for North America and Europe, which provides market shares of the top 3–5 key players in the leukapheresis market

Competitive leadership mapping for established players in the US

 

Get the Full Leukapheresis Market Report

Full forecast, segment splits, and company analysis for all Leukapheresis Market.

Need a Tailored Report?

Customize this report to your needs

Get 10% FREE Customization

Customize This Report
Fact checked
DMCA.com Protection Status